199 related articles for article (PubMed ID: 24618304)
1. The role of thiopurine metabolites in inflammatory bowel disease and rheumatological disorders.
Friedman AB; Sparrow MP; Gibson PR
Int J Rheum Dis; 2014 Feb; 17(2):132-41. PubMed ID: 24618304
[TBL] [Abstract][Full Text] [Related]
2. Review article: thiopurines in inflammatory bowel disease.
Derijks LJ; Gilissen LP; Hooymans PM; Hommes DW
Aliment Pharmacol Ther; 2006 Sep; 24(5):715-29. PubMed ID: 16918876
[TBL] [Abstract][Full Text] [Related]
3. Use of thiopurines in inflammatory bowel disease.
Frei P; Biedermann L; Nielsen OH; Rogler G
World J Gastroenterol; 2013 Feb; 19(7):1040-8. PubMed ID: 23467510
[TBL] [Abstract][Full Text] [Related]
4. Thiopurine methyl-transferase activity and azathioprine metabolite concentrations do not predict clinical outcome in thiopurine-treated inflammatory bowel disease patients.
González-Lama Y; Bermejo F; López-Sanromán A; García-Sánchez V; Esteve M; Cabriada JL; McNicholl AG; Pajares R; Casellas F; Merino O; Carpio D; Vera MI; Muñoz C; Calvo M; Benito LM; Bujanda L; García-Fernández FJ; Ricart E; Ginard D; Velasco M; Carneros JA; Manceñido N; Calvo M; Algaba A; Froilan C; Cara C; Maté J; Abreu L; Gisbert JP;
Aliment Pharmacol Ther; 2011 Sep; 34(5):544-54. PubMed ID: 21722149
[TBL] [Abstract][Full Text] [Related]
5. Thiopurine therapy in inflammatory bowel disease.
Ha C; Dassopoulos T
Expert Rev Gastroenterol Hepatol; 2010 Oct; 4(5):575-88. PubMed ID: 20932143
[TBL] [Abstract][Full Text] [Related]
6. Role of thiopurine metabolite testing and thiopurine methyltransferase determination in pediatric IBD.
Benkov K; Lu Y; Patel A; Rahhal R; Russell G; Teitelbaum J;
J Pediatr Gastroenterol Nutr; 2013 Mar; 56(3):333-40. PubMed ID: 23287804
[TBL] [Abstract][Full Text] [Related]
7. On therapeutic drug monitoring of thiopurines in inflammatory bowel disease; pharmacology, pharmacogenomics, drug intolerance and clinical relevance.
Van Asseldonk DP; de Boer NK; Peters GJ; Veldkamp AI; Mulder CJ; Van Bodegraven AA
Curr Drug Metab; 2009 Nov; 10(9):981-97. PubMed ID: 20214590
[TBL] [Abstract][Full Text] [Related]
8. The role of thiopurine metabolite monitoring in inflammatory bowel disease.
Beswick L; Friedman AB; Sparrow MP
Expert Rev Gastroenterol Hepatol; 2014 May; 8(4):383-92. PubMed ID: 24684593
[TBL] [Abstract][Full Text] [Related]
9. Usefulness of mean corpuscular volume as a surrogate marker for monitoring thiopurine treatment in inflammatory bowel disease.
Dujardin RW; Meijer B; de Boer NK; D'Haens GR; Löwenberg M
Eur J Gastroenterol Hepatol; 2016 Sep; 28(9):991-6. PubMed ID: 27257870
[TBL] [Abstract][Full Text] [Related]
10. Review article: the benefits of pharmacogenetics for improving thiopurine therapy in inflammatory bowel disease.
Chouchana L; Narjoz C; Beaune P; Loriot MA; Roblin X
Aliment Pharmacol Ther; 2012 Jan; 35(1):15-36. PubMed ID: 22050052
[TBL] [Abstract][Full Text] [Related]
11. Thiopurines in Pediatric Inflammatory Bowel Disease: Current and Future Place.
van Hoeve K; Vermeire S
Paediatr Drugs; 2020 Oct; 22(5):449-461. PubMed ID: 32797366
[TBL] [Abstract][Full Text] [Related]
12. Allopurinol might improve response to azathioprine and 6-mercaptopurine by correcting an unfavorable metabolite ratio.
Gardiner SJ; Gearry RB; Burt MJ; Chalmers-Watson T; Chapman BA; Ross AG; Stedman CA; Huelsen A; Barclay ML
J Gastroenterol Hepatol; 2011 Jan; 26(1):49-54. PubMed ID: 21175793
[TBL] [Abstract][Full Text] [Related]
13. Dosing 6-thioguanine in inflammatory bowel disease: expert-based guidelines for daily practice.
Seinen ML; van Asseldonk DP; Mulder CJ; de Boer NK
J Gastrointestin Liver Dis; 2010 Sep; 19(3):291-4. PubMed ID: 20922194
[TBL] [Abstract][Full Text] [Related]
14. Evolving Considerations for Thiopurine Therapy for Inflammatory Bowel Diseases-A Clinical Practice Update: Commentary.
Hanauer SB; Sandborn WJ; Lichtenstein GR
Gastroenterology; 2019 Jan; 156(1):36-42. PubMed ID: 30195449
[TBL] [Abstract][Full Text] [Related]
15. Thiopurines during pregnancy in inflammatory bowel disease: is there a risk for the (unborn) child?
de Boer NK; de Meij T; van Bodegraven AA
Expert Rev Gastroenterol Hepatol; 2013 Nov; 7(8):669-71. PubMed ID: 24134152
[No Abstract] [Full Text] [Related]
16. Melanoma and non-melanoma skin cancer in inflammatory bowel disease patients following tumor necrosis factor-α inhibitor monotherapy and in combination with thiopurines: analysis of the Food and Drug Administration Adverse Event Reporting System.
McKenna MR; Stobaugh DJ; Deepak P
J Gastrointestin Liver Dis; 2014 Sep; 23(3):267-71. PubMed ID: 25267954
[TBL] [Abstract][Full Text] [Related]
17. Novel strategies in the thiopurine treatment of inflammatory bowel disease.
Almer S
Nucleosides Nucleotides Nucleic Acids; 2010 Jun; 29(4-6):267-77. PubMed ID: 20544506
[TBL] [Abstract][Full Text] [Related]
18. Thiopurine methyltransferase activity combined with 6-thioguanine metabolite levels predicts clinical response to thiopurines in patients with inflammatory bowel disease.
Kwan LY; Devlin SM; Mirocha JM; Papadakis KA
Dig Liver Dis; 2008 Jun; 40(6):425-32. PubMed ID: 18304898
[TBL] [Abstract][Full Text] [Related]
19. Difficulties and possibilities with thiopurine therapy in inflammatory bowel disease--proceedings of the first Thiopurine Task Force meeting.
van Asseldonk DP; Sanderson J; de Boer NK; Sparrow MP; Lémann M; Ansari A; Almer SH; Florin TH; Gearry RB; Mulder CJ; Mantzaris G; van Bodegraven AA;
Dig Liver Dis; 2011 Apr; 43(4):270-6. PubMed ID: 20934926
[TBL] [Abstract][Full Text] [Related]
20. Randomised clinical trial: efficacy, safety and dosage of adjunctive allopurinol in azathioprine/mercaptopurine nonresponders (AAA Study).
Friedman AB; Brown SJ; Bampton P; Barclay ML; Chung A; Macrae FA; McKenzie J; Reynolds J; Gibson PR; Hanauer SB; Sparrow MP
Aliment Pharmacol Ther; 2018 Apr; 47(8):1092-1102. PubMed ID: 29468701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
